Johnson & Johnson (NYSE:JNJ) Stock Position Lowered by Bank OZK

Bank OZK cut its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,502 shares of the company’s stock after selling 248 shares during the period. Bank OZK’s holdings in Johnson & Johnson were worth $2,039,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Family CFO Inc purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at $26,000. Steward Financial Group LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at $34,000. Joseph P. Lucia & Associates LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at $38,000. Advocacy Wealth Management Services LLC grew its holdings in shares of Johnson & Johnson by 41.4% during the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after buying an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at $49,000. 68.78% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

JNJ opened at $171.79 on Friday. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42. The company has a market cap of $451.67 billion, a PE ratio of 25.01, a price-to-earnings-growth ratio of 3.29 and a beta of 0.59. The stock has a 50-day moving average of $175.41 and a 200-day moving average of $174.52.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the previous year, the firm earned $2.48 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. As a group, equities research analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. UBS Group lowered their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. SVB Leerink lowered their target price on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Daiwa Capital Markets started coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating on the stock. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Finally, Citigroup lowered their target price on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.